Table 1.
Characteristics and results of studies on laser ablation of recurrent thyroid cancers
| Study | Year | No. of patients | No. of treated tumours | Tumour dimensions | Result |
|---|---|---|---|---|---|
| Papini et al. [15] | 2013 | 5 | 8 | Mean: 0.64±0.58 mL | Technical success: 100%; no major complications |
| 12-Month follow-up | |||||
| Mean volume reduction 87.72%±0.11% | |||||
| Mean serum Tg on LT4 decreased from 8.0±3.2 to 2.0±2.5 ng/mL | |||||
| Undetectable serum levels of Tg: 3/5 patients (60%) | |||||
| Mauri et al. [14]a) | 2013 | 15 | 24 | Mean: 1.1±0.4 cm (range, 0.6-1.6 cm) | Technical success: 100%; no major complications |
| 6-Month follow-up | |||||
| Local control: 11/15 patients (73%) | |||||
| Negative on 18FDG-PET/CT and CEUS: 20/24 nodes (83%) | |||||
| Normalized serum Tg/TgAb: 6/15 patients (40%) | |||||
| 12-Month follow-up | |||||
| Local control: 10/14 patients (71.4%) | |||||
| Negative on 18FDG-PET/CT and CEUS: 16/20 nodes (80%) | |||||
| Normalized serum Tg/TgAb: 4/10 patients (40%) | |||||
| Mauri et al. [24] | 2016 | 24 | 46 | Mean: 1.0±0.5 cm (range, 0.6-1.6 cm) | Technical success: 100%; no major complications |
| Mean follow-up of 30±11 months | |||||
| Tg decreased from 8.40±9.25 to 2.73±4.00 ng/mL | |||||
| Tg/TgAb normalized: 11/24 patients (45.8%) | |||||
| Local control: 40/46 lymph nodes (86.9%), no residual disease at imaging: 19/24 patients (79.1%) | |||||
| Estimated mean time to progression: 38.6±2.7 months | |||||
| Zhou et al. [70] | 2016 | 21 | 27 | Mean volume: 105.42±114 mm3 | Technical success: 100%; no major complications |
| Completely treated with 1 ablation: 24/27 lymph nodes (88.8%), | |||||
| completely treated with 2 ablations: 3/27 (12.2%) | |||||
| Significant volumetric reduction to 0.8-2.4 mm3 at the final follow-up | |||||
| No regrowth or new lesions at US during follow-up | |||||
| Zhang et al. [69] | 2018 | 17 | 21 | Mean volume: 0.110±0.125 mL (interquartile range, 0.01-0.536 mL) | Technical success: 100%; no major complications |
| Completely ablated in 1 ablation: 18/21 cases (85.7%), completely ablated with 2 ablations: 3/21 (14.3%) | |||||
| Mean follow-up of 17.86±4.704 months (interquartile range, 12-27 months): no evident recurrence on US |
Tg, thyroglobulin; LT4, levothyroxine; 18FDG-PET/CT, 18-Fludeoxyglucose positron emission tomography computed tomography; CEUS, contrast-enhanced ultrasonography; TgAb, anti-thryoglobulin antibody; US, ultrasonography.
a)
Preliminary results.